Business Description
NuCana PLC
ISIN : US67022C1062
Share Class Description:
FRA:N040: ADRTotal Employee Number:
12Description
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 31.65 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 86.7 | |||||
3-Year FCF Growth Rate | 88.3 | |||||
3-Year Book Growth Rate | -88.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 45.12 | |||||
12-1 Month Momentum % | -51.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.48 | |||||
Quick Ratio | 5.48 | |||||
Cash Ratio | 4.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -646.6 | |||||
Shareholder Yield % | -457.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -184.25 | |||||
ROA % | -132.13 | |||||
ROIC % | -677.63 | |||||
3-Year ROIIC % | -327.7 | |||||
ROC (Joel Greenblatt) % | -6362.75 | |||||
ROCE % | -133.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | 0.09 | |||||
PB Ratio | 0.2 | |||||
Price-to-Tangible-Book | 0.22 | |||||
EV-to-EBIT | 0.71 | |||||
EV-to-EBITDA | 0.72 | |||||
EV-to-FCF | 2.1 | |||||
Price-to-Graham-Number | 0.03 | |||||
| Price-to-Net-Current-Asset-Value | 0.23 | |||||
| Price-to-Net-Cash | 0.27 | |||||
Earnings Yield (Greenblatt) % | 140.85 | |||||
FCF Yield % | -177.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NuCana PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | - | ||
| Beta | -2.0979 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 51.4 | ||
| Volatility % | 65.25 | ||
| 14-Day RSI | 45.12 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 3.2 | ||
| 12-1 Month Momentum % | -51.52 | ||
| 52-Week Range (€) | 3.2 - 17.6 | ||
| Shares Outstanding (Mil) | 4.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NuCana PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NuCana PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 43 days | ||
| General meeting for 2026 | 2026-06-08 10:00 | 3.20 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 3.20 (+0.00%) | ||
| Annual report for 2025 | 2026-03-19 | 3.20 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 3.20 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 3.20 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 3.20 (+0.00%) | ||
| 0.005:1 Stock Split | 2025-08-11 | 3.20 (+0.00%) | ||
| General meeting for 2025 | 2025-06-27 10:00 | 12.20 (+0.00%) |
Show
Entries
NuCana PLC Frequently Asked Questions
What is NuCana PLC(FRA:N040)'s stock price today?
The current price of FRA:N040 is €3.20. The 52 week high of FRA:N040 is €17.60 and 52 week low is €3.20.
When is next earnings date of NuCana PLC(FRA:N040)?
The next earnings date of NuCana PLC(FRA:N040) is 2026-08-20 Est..
Does NuCana PLC(FRA:N040) pay dividends? If so, how much?
NuCana PLC(FRA:N040) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on NuCana PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers